help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This version published online on March 7, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2005-2654
A more recent version of this article appeared on June 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/6/2447    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamagishi, S.-i.
Right arrow Articles by Imaizumi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamagishi, S.-i.
Right arrow Articles by Imaizumi, T.

Submitted on December 7, 2005
Accepted on March 1, 2006

Elevated serum levels of pigment epithelium-derived factor (PEDF) in the metabolic syndrome

Sho-ichi Yamagishi MD, PhD*, Hisashi Adachi MD, PhD, Akio Abe, Takako Yashiro, Mika Enomoto MD, Kumiko Furuki MD, Asuka Hino PhD, Yuko Jinnouchi MD, Katsuhiko Takenaka MD, Takanori Matsui PhD, Kazuo Nakamura MD, and Tsutomu Imaizumi MD, PhD

Department of Internal Medicine III, Kurume University School of Medicine, Kurume (S.Y., H.A., M.E., K.F., A.H., Y.J., K.T., T.M., K.N., T.I.), and Cytokine Section, SRL Inc., Kanagawa (A.A., T.Y.), Japan

* To whom correspondence should be addressed. E-mail: shoichi{at}med.kurume-u.ac.jp.

Context: Pigment epithelium-derived factor (PEDF), a potent inhibitor of angiogenesis with neuronal differentiating activity, inhibits endothelial cell injury in vitro, thus suggesting the involvement of PEDF in atherosclerosis. Therefore, to elucidate the relationship between serum levels of PEDF and coronary risk factors could provide a clue to understanding the pathophysiological role of PEDF in vivo.

Objective: We examined whether serum levels of PEDF were associated with risk factors for coronary artery disease.

Design: Cross-sectional study.

Setting: General community.

Patients or Other participants: A total of 196 general Japanese residents (age 65.7 ± 9.3 yr; 71 males and 125 females) without clinical evidence of coronary or peripheral arterial occlusive diseases were enrolled in this study.

Results: PEDF showed a normal distribution, ranging from 8 to 24 µg/ml with the mean of 14.6 ± 3.2 µg/ml. Multivariate analyses revealed that uric acid (P < 0.001), waist circumference (P = 0.009), insulin (P = 0.019), and triglycerides (P = 0.028) were significant independent determinants of serum PEDF levels. Age- and uric acid-adjusted PEDF levels were significantly higher (P = 0.048 for men and P = 0.007 for women) in proportion to the accumulation of the number of the components of the metabolic syndrome.

Conclusions: The present study reveals that serum levels of PEDF are strongly associated with the metabolic syndrome. Our results suggest that serum PEDF levels may be elevated as a counter-system in the metabolic syndrome.
Key words: metabolic syndrome • oxidative stress • atherosclerosis • PEDF




This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
T. Fujimura, S.-i. Yamagishi, S. Ueda, K. Fukami, R. Shibata, Y. Matsumoto, Y. Kaida, A. Hayashida, K. Koike, T. Matsui, et al.
Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats
Nephrol. Dial. Transplant., November 28, 2008; (2008) gfn659v1.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
B.-S. Youn, N. Kloting, J. Kratzsch, N. Lee, J. W. Park, E.-S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, et al.
Serum Vaspin Concentrations in Human Obesity and Type 2 Diabetes
Diabetes, February 1, 2008; 57(2): 372 - 377.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
M. Yokoi, S.-i. Yamagishi, A. Saito, Y. Yoshida, T. Matsui, W. Saito, S. Hirose, K. Ohgami, M. Kase, and S. Ohno
Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy
Br. J. Ophthalmol., July 1, 2007; 91(7): 885 - 887.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
Y. Yoshida, S.-i. Yamagishi, T. Matsui, K. Nakamura, T. Imaizumi, K. Yoshimura, and R. Yamakawa
Positive correlation between pigment epithelium-derived factor and monocyte chemoattractant protein-1 levels in the aqueous humour of patients with uveitis
Br. J. Ophthalmol., June 1, 2007; 91(6): 737 - 738.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Ogata, M. Matsuoka, K. Matsuyama, C. Shima, A. Tajika, T. Nishiyama, M. Wada, N. Jo, A. Higuchi, K. Minamino, et al.
Plasma Concentration of Pigment Epithelium-Derived Factor in Patients with Diabetic Retinopathy
J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1176 - 1179.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
Y. Motomiya, S.-i. Yamagishi, H. Adachi, and A. Abe
Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease.
Clin. Chem., October 1, 2006; 52(10): 1970 - 1971.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society